SOSV is a global venture capital firm headquartered in Princeton, New Jersey, focused on seed-to-growth investments in deep tech, life sciences, hardware and software, with a strong emphasis on human and planetary health. The company operates startup development programs such as HAX and IndieBio, offering facilities, labs, engineering resources, mentorship, and collaborative workspaces to help founders advance technology and accelerate fundraising. Beyond capital, SOSV provides hands-on support to accelerate product development, customer acquisition and scaling, connecting portfolio companies with a global network of partners and investors. Its ecosystem spans multiple regions and markets, including cross-border ventures in Asia, and it maintains a portfolio of startups that have progressed to subsequent funding rounds. In addition to direct investments, SOSV’s programs and resources are designed to help early-stage companies mature toward scalable, sustainable growth while fostering innovation across sectors that address health, climate, and technology challenges.

OrbiMed is a global healthcare investment firm founded in 1989 and based in New York, with a worldwide presence that includes offices in several regions. It allocates capital across private equity, venture capital, and public equity to support healthcare companies at various stages, from startups to established firms. Its focus spans biopharmaceuticals, medical devices, diagnostics, life sciences tools, and digital health, as well as healthcare services. The firm pursues opportunities across major markets in North America, Europe, and Asia, often leveraging region-specific teams to invest in companies in Israel, China, India, South Korea, and other jurisdictions. OrbiMed emphasizes building world-class companies by providing strategic financing, industry expertise, and global resources to portfolio companies in pursuit of medical breakthroughs and sustainable growth.

RA Capital Management is a Boston-based investment management firm specializing in growth-oriented and early-stage support for healthcare, life sciences, and planetary health companies. The company deploys capital across private seed rounds, series financings, and public markets, with a focus on drugs, medical devices, diagnostics, and tools that advance patient care. It leverages a science-driven approach through its research platform TechAtlas and provides value-added services such as board representation, executive recruitment, and market intelligence to portfolio companies. The firm operates an incubator program called Raven to nurture biomedical innovation and maintains an Innovator Resources program to guide company development. RA Capital emphasizes evidence-based investing, long-term partnerships, and social responsibility, aiming to drive value creation from inception through commercialization.

Eli Lilly and Company is a global pharmaceutical company engaged in discovery, development, manufacture, and sale of medicines. It operates with facilities in the United States, Puerto Rico, and numerous other countries, and its products are sold in about 135 countries. The company conducts research to address human diseases and also pursues animal health research and products to support animal health and agricultural production. Lilly emphasizes patient support, safety, and quality manufacturing, and pursues ongoing innovation in areas such as neuroscience, cardiometabolic disease, cancer, and immunology to bring new therapies to patients worldwide.

Novo Nordisk is a global healthcare company focused on discovering, developing, and delivering medicines for chronic diseases, with insulin and diabetes care at its core. It develops and distributes insulin and other diabetes therapies, and invests heavily in scientific research and biotechnology to advance breakthroughs. The company operates worldwide, aiming to expand access to its treatments and improve patient outcomes, while emphasizing sustainability, partnerships, and social responsibility.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. It provides seed through growth capital to life science and technology companies developing breakthrough therapies, diagnostics, research tools, agrifoodtech, agtech, digital health, and related platforms. Backed by the parent company’s industry experience and scientific advisory network, the firm leverages long-standing relationships and domain expertise to support early to growth-stage ventures aiming to translate scientific advances into practical healthcare and technology solutions.

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong and Singapore. It backs early and growth-stage technology, consumer and healthcare companies, applying deep industry knowledge and hands-on support to help portfolio companies scale. The firm manages US-dollar and RMB funds and maintains a global footprint, including a dedicated US arm, Qiming Venture Partners USA, to pursue cross-border opportunities in healthcare, therapeutics and digital health. Since inception, it has invested in more than 530 companies and achieved more than 200 exits via IPOs, M&A or other means, with over 70 portfolio companies reaching unicorn or super unicorn status. Qiming emphasizes long-term partnerships with entrepreneurs, aligning resources and networks to drive innovation and societal progress across its portfolio.

ARCH Venture Partners is a Chicago-based venture capital firm that backs science-driven startups across life sciences, biotechnology, health tech, and related technologies. Founded in 1986, the firm emphasizes innovations developed in academic research institutions and national laboratories, providing long-term, hands-on support from inception through scalable growth. ARCH targets companies co-founded by scientists and entrepreneurs, seeks to accelerate medical and technological breakthroughs, and aims to translate research into commercial products. The firm invests across stages, often from early rounds to later-stage financing, and collaborates with a broad mix of corporate, financial, and private investors. ARCH operates with a national and international reach, funding companies in the United States and beyond, with a focus on disruptive science aimed at preventing, detecting, and treating diseases.

Invus is a private investment firm founded in 1985 and based in New York with a global footprint. It partners with entrepreneurs and owner-managers to drive transformative growth through flexible, long-term capital and customized investment approaches. The firm aligns its incentives with management and pursues opportunities across private equity and selective co-investments, leveraging an evergreen capital base to support portfolio companies through bumps and cycles. Invus operates globally with offices in New York, London, Paris, and Hong Kong and focuses on companies with competitive advantages in consumer, technology, and life sciences sectors, among others.

Sofinnova Partners is an independent venture capital firm based in Paris, France, focusing on life sciences. It finances start-ups, early-stage companies, corporate spin-offs, and occasional turnarounds in biopharmaceuticals, biotech, medical devices, and related areas. The firm often acts as a lead or cornerstone investor and is frequently the first institutional backer in Series A rounds, maintaining an active role including board seats from formation through exit. It pursues global opportunities and emphasizes thorough due diligence on portfolio companies, including management and intellectual property considerations. The firm was established in 1972.

Morningside Group is a venture capital firm founded in 1986, originally established as a family office for the Chan family, and is based in the greater Boston area. The firm makes venture investments in companies with novel science and technology, pursuing a long-term, patient approach to company-building and emphasizing ethical practices. Its investment focus spans life sciences, digital health, artificial intelligence, materials science, and information technology. In addition to its investment activities, Morningside supports charitable initiatives in education, research, and healthcare, with partnerships including the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

Samsara BioCapital is a venture capital firm based in Palo Alto, California, that invests in biotechnology and healthcare companies across the United States. The firm supports biotech ventures by providing capital and strategic guidance to help advance innovative therapies and discoveries. It operates as a registered investment adviser, offering investment advisory services to entrepreneurs and venture teams as they work to bring new biotech solutions to market.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco, with offices in Canada, the United States, and Europe. The firm invests across the healthcare sector at all stages, with emphasis on the discovery and development of novel therapeutics, including pharmaceuticals, biotechnology, medical devices, and life sciences. Versant combines investment, operating, and scientific expertise to support portfolio companies through strategic guidance and hands-on involvement in company building. The firm manages substantial capital, enabling a hands-on approach to helping entrepreneurs build durable companies addressing high unmet medical needs.

Mission BioCapital is a life science venture capital firm focused on funding early-stage biotechnology and related life sciences companies. Based in Cambridge, Massachusetts, the firm has a long history of collaborating with portfolio companies and supporting entrepreneurs beyond capital, offering mentorship, strategic guidance, and access to laboratory space in the United States and Europe. Since 2009, it has operated multiple funds, including a fifth fund, and runs programs such as a Platinum Program that provides early-stage funding up to 500,000 and practical support in areas such as drug discovery, legal, accounting, and scientific mentorship to accelerate development from concept to clinical milestones.

Khosla Ventures is a California-based venture capital firm founded in 2004 by Vinod Khosla. The firm backs entrepreneurs with venture assistance, strategic guidance, and capital, focusing on bold, early-stage technology companies. It invests across sectors including AI, climate and sustainability, enterprise software, consumer technologies, fintech, digital health, medtech and diagnostics, therapeutics, and frontier technologies. Based in Menlo Park, the firm manages several funds to support startups across stages, prioritizing ventures that address large markets and have potential for significant social and economic impact.

Casdin Capital is an investment firm focused on life sciences and healthcare. Founded in 2012 by Eli Casdin and based in New York, it seeks opportunities across the life sciences spectrum, including biotechnology, digital health, oncology, agtech, and healthcare services. The firm pursues early- to late-stage private investments and, at times, long-short equity strategies, leveraging data-driven insights, molecular information, and precision medicine to identify transformative opportunities. It emphasizes patient capital, disciplined investing, and strong collaborations to support companies advancing diagnostics, therapeutics, and sustainable solutions. By capturing and processing data to unlock breakthroughs, Casdin Capital backs teams with the potential to transform modern medicine.

Pfizer is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines across a broad range of therapeutic areas. It maintains an extensive portfolio of prescription drugs and vaccines, with notable products such as Prevnar 13, Ibrance, and Eliquis. The company serves customers worldwide, with substantial international and emerging-market sales. Through ongoing research and development, Pfizer pursues new treatments to address major diseases, including cancer and neurodegenerative conditions, and aims to improve patient outcomes by delivering safe, effective, and accessible therapies. Founded in 1849 and headquartered in the United States, Pfizer operates globally to advance health care through science, partnerships, and scalable manufacturing capabilities.

New Enterprise Associates is a U.S.-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across stages and geographies, supporting startups from seed to growth. The firm operates globally with investments in the United States, Asia, and Brazil among others, and has a long track record of portfolio IPOs and acquisitions. It has over $19 billion in cumulative committed capital.

Polaris Partners is a venture capital firm based in Boston, Massachusetts, founded in 1996. It invests in technology and life sciences companies across the United States and Europe, supporting multiple stages from early development to growth. Its portfolio spans software, healthcare information technology, digital health, biotechnology, pharmaceuticals, and related life sciences, with emphasis on molecules, platforms, therapeutics, genomics, and data-driven healthcare solutions. The firm maintains a presence in Boston and San Francisco and emphasizes deep engagement with founders, offering strategic guidance and network resources to accelerate growth.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. Based in Palo Alto, California, with offices in New York City, it specializes in seed and early-stage investments across technology and healthcare, including information technology, software, cybersecurity, genomics, and digital health. The firm supports entrepreneurs with capital, strategic guidance, and access to its network to help build enduring companies. Notable portfolio entries include Apple, Illumina, Gilead Sciences, Intel, Nest, Endeca, and SlideShare, reflecting a history of backing influential technology and life sciences ventures.

Redmile Group is a San Francisco-based private equity firm with an office in New York that focuses on investments in the healthcare sector, pursuing opportunities across venture, growth, and crossover stages to support healthcare companies with strategic capital and partnerships.

Deerfield Management is a New York-based healthcare investment firm founded in 1994. It pursues long-term investments across therapeutics, medical devices, diagnostics, digital health, and healthcare services, managing a diverse portfolio of private and public investments. The firm combines investment activity with information gathering and philanthropy, leveraging Deerfield Intelligence, market research, and data-driven insights to inform decisions. It operates initiatives such as Deerfield Discovery and Development and supports charitable work through the Deerfield Foundation, focusing on improving children’s health worldwide. Through its strategy of connecting capital, ideas, and technology, Deerfield Management seeks to advance human health by supporting innovation across the healthcare ecosystem.

Vivo Capital is a global healthcare investment firm founded in 1996 and based in Palo Alto, California, with offices in Asia. It operates a multi-fund platform spanning growth equity, private equity including buyouts, venture capital, and public equity, and invests broadly in biotechnology, pharmaceuticals, medical devices, and healthcare services across major markets. The firm pursues opportunities worldwide, supporting companies at various development stages with a team of physicians, scientists, entrepreneurs, operating executives, and industry experts who contribute deep sector insight. It manages approximately $5.8 billion in assets under management.

Atlas Venture is a Cambridge, Massachusetts-based biotech venture capital firm with a 30-year track record of building breakthrough companies in life sciences. It concentrates on translating innovative biology into medicines through early-stage, seed-led venture creation and investments in life sciences and technology startups. The firm typically serves as a lead investor and seeks board representation to help guide portfolio companies, aiming to build scalable businesses and realize value. Atlas Venture has supported the development of multiple medicines and launched startups through its incubator program, reflecting its emphasis on scientific translation and entrepreneurship.

Forbion is a global venture capital firm based in Naarden, Netherlands, focused on biotech innovations and sustainable solutions to improve human and planetary health. It invests across human health, planetary health, and the bioeconomy, supporting companies from preclinical stages to growth, across Europe and North America. With two decades of experience, Forbion combines venture funding with active company building and expansion support, while integrating ESG principles to drive responsible, impactful growth.

Northpond Ventures is a science-driven venture capital firm specializing in growth capital, headquartered in Bethesda, Maryland, with offices in San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, it focuses on life sciences and technology sectors, including diagnostics, digital health, health tech, therapeutics, and artificial intelligence and machine learning. The firm backs growth-stage companies advancing biomedical research and technology-enabled healthcare, aiming to translate scientific advances into commercial solutions.

The Column Group is a San Francisco-based venture capital firm that invests in biotechnology and life sciences companies, with a focus on drug discovery, oncology, and technology-enabled healthcare. The firm supports companies from early discovery through later-stage development, pursuing a long-term, platform-based approach designed to generate multiple product opportunities rather than a single exit. It backs startups addressing cancer, inflammation, infectious disease, metabolic, cardiovascular, and nervous system disorders, typically allocating between $15 million and $30 million per deal. The Column Group manages over $4 billion in assets and operates as an investment adviser, leveraging a nationwide US focus for opportunities in healthcare and related sectors.

EcoR1 Capital is a San Francisco-based investment firm focused on the biotechnology sector. Founded in 2012, the company operates as an investment adviser and venture investor, seeking to identify and support innovative therapeutic solutions with the potential to improve patient outcomes. It provides investment services to pooled vehicles and participates in biotech investments across private and public markets, reflecting a commitment to advancing medical research.

F-Prime Capital is a venture capital firm founded in 1969 and based in Cambridge, Massachusetts. It invests globally in sectors including crypto, enterprise information technology, fintech, frontier tech, health information technology and services, medtech, and therapeutics, as well as broader technology companies. The firm maintains lean, entrepreneurially oriented teams in the United States and Europe and supports founders with domain expertise and industry relationships to help build meaningful, scalable businesses. With a history of backing notable technology and life sciences entrepreneurs, F-Prime Capital focuses on helping early-stage companies achieve breakthrough growth while maintaining a long-term, collaborative partnership with portfolio teams.

Logos Capital is a biotechnology-focused investment firm headquartered in San Francisco. The company applies disciplined, data-driven diligence across medical, scientific, and clinical disciplines to identify transformative therapies in healthcare. By combining in-house analytics with rigorous clinical evaluation, Logos Capital seeks to back life-changing therapeutics with strong value propositions. The firm emphasizes rigorous opportunity identification, thorough clinical trial underwriting, and proactive risk management, leveraging advanced analytics to predict trial outcomes and support informed investment decisions. Its approach aims to deliver compelling returns while contributing to patient outcomes by supporting companies with transformative technologies.

Alumni Ventures Group is a venture capital firm based in Manchester, New Hampshire, founded in 2013. It connects accredited individual investors—especially alumni from top entrepreneurial schools—to venture opportunities by pooling investments and backing companies with alumni connections alongside institutional lead investors. The firm offers diversified portfolios through focused funds, syndicates, and investing clubs, enabling access to venture deals across sectors, stages, and geographies. It emphasizes transparency, due diligence, and co-investment with established venture capital firms.

Sofinnova Investments is a venture capital firm founded in 1976 and headquartered in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It backs life sciences and information technology companies across the United States and Europe, from seed through early and growth stages. In life sciences, it targets clinical-stage pharmaceutical and biotechnology companies, drug discovery platforms, and medical technology addressing diseases with unmet medical needs, including oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it supports product-oriented software, enterprise IT solutions and telecommunications infrastructure. The firm often requires board participation for early-stage lead or co-lead investments and emphasizes hands-on guidance to help entrepreneurs build global businesses.

HBM Healthcare Investments is a Swiss investment firm founded in 2001 that focuses on delivering access to a globally diversified portfolio of healthcare companies. Headquartered in Switzerland, the firm targets opportunities across human medicine, biotechnology, medical technology and diagnostics, investing in both private and public companies with established or near-market products. It emphasizes active portfolio management and provides strategic guidance to portfolio companies to support value creation. By leveraging demographic trends and medical innovation, the firm seeks attractive returns while maintaining a diversified asset mix that includes private holdings, public equities and funds. The company is noted for an attractive dividend policy with a yield around five percent.

Merck KGaA is a German science and technology company founded in 1668 in Darmstadt. It operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments for researchers in academia and industry; the Electronics segment supplies specialty materials used in manufacturing semiconductors and displays; the Healthcare segment develops branded pharmaceuticals with therapeutic focus areas including oncology, neurology and immunology, fertility and metabolic diseases. Outside the United States and Canada, the Merck name is used globally; in North America, healthcare operates as Merck Serono, life science as MilliporeSigma, and electronics as EMD Electronics. Merck has a long history as one of the world’s oldest operating chemical and pharmaceutical companies and maintains a global presence across Europe, Africa, Asia, Oceania and Latin America, with the founding family retaining a majority ownership.

Omega Funds is a Boston-based venture capital firm founded in 2004 that focuses on funding early-stage healthcare and biotechnology companies in North America and Western Europe. The firm backs ventures across life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, seeking to advance therapies, platforms, and digital health solutions. With a seasoned team and extensive industry network, Omega Funds collaborates with exceptional founders to improve clinical and commercial success in the healthcare sector.

Flagship Pioneering is a Cambridge, Massachusetts-based venture creation firm that conceives, creates, resources, and grows first-in-category ventures to transform human health, sustainability, and related fields. It fuses scientific discovery with entrepreneurial leadership and professional capital to systematically build companies at the frontier of biology, engineering, medicine, energy, and beyond. The firm pursues ambitious, seemingly unreasonable propositions and steers them through an evolutionary development process to achieve transformational outcomes. By combining deep scientific insight with a structured, capital-backed platform, Flagship Pioneering accelerates progress in health technology, biotechnology and life sciences.

SR One Capital Management is the corporate venture capital arm of GlaxoSmithKline. A transatlantic biotechnology venture firm, it invests globally in life sciences companies pursuing innovative science with potential to improve medical care. Based in Redwood City, California, with a presence in London, it provides strategic reach and regional support to portfolio companies across the United States and Europe. The firm follows a back‑and‑build approach, prioritizing companies with strong fundamentals, clear development plans, and novel solutions to disease. Since its founding in 1985, SR One has backed hundreds of ventures and invested approximately 800 million in more than 180 companies, advancing pharmaceuticals, biotech devices, and related life science technologies.

Deep Track Capital is a Greenwich, Connecticut-based venture capital firm focused on life sciences and biotechnology. It partners with management teams of innovative public and pre-IPO companies, providing capital, strategic expertise, and access to its industry network to support growth. The firm aims to lead transactions and form large syndicates, while collaborating with other investors to fund rounds and accelerate development of healthcare solutions.

IP Group is a global science and technology investment company focused on identifying, backing, and growing early‑stage, science‑based businesses. It commercialises intellectual property originating from research‑intensive institutions, managing the process from IP discovery to business development or the formation of strategic partnerships. The firm concentrates on HealthTech, DeepTech, and CleanTech, backing university spin‑outs and other innovative ventures with the potential to disrupt markets and deliver strong financial returns while delivering social and environmental impact aligned with the UN Sustainable Development Goals. IP Group leverages expertise in investment case development, governance, results reporting, and regulatory affairs, and cultivates collaborations with leading research institutions to accelerate growth. As a catalyst for innovation, it provides capital, strategic guidance, and operational support to portfolio companies to translate scientific advances into scalable technologies that benefit society and the economy.

Boxer Capital is a biotechnology investment firm that invests in private and public companies across the full drug development lifecycle, from early discovery to late-stage clinical and commercial programs. Based in the United States, it operates as part of the Tavistock Group and concentrates on biotechnology, life sciences, and precision and specialized medicine. The firm emphasizes disciplined, science-driven analysis and a multidisciplinary approach, with bottom-up idea generation supported by experienced scientists, aiming to advance innovative targets and therapies that improve patient care. It pursues opportunistic venture investments across private and public markets.

MPM Capital is a healthcare investment firm that finances biotechnology, life sciences, and medical technologies with the aim of translating science into clinical outcomes. The firm backs companies across stages from seed through late venture and growth, including oncology, medical devices, specialty pharma, and diagnostics, with investments typically spanning global opportunities in the United States, Europe, and Asia. It often serves as a lead investor and may take interim operating roles to support portfolio companies, leveraging a three-decade track record in building biotechnology and healthcare companies.

Takeda is a global biopharmaceutical company based in Japan that discovers, develops, manufactures, and markets prescription medicines and vaccines. Its core therapeutic areas include oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which together account for a large share of revenue. The company operates worldwide with a diversified geographic footprint, generating significant portions of revenue from the United States, Japan, Europe and Canada. Takeda emphasizes research and development to address unmet medical needs and focuses on strategic areas through internal programs and collaborations. The organization seeks to improve patient outcomes and access to medicines, while pursuing sustainable practices and long-term value for stakeholders.

Kurma Partners is a Paris-based investment firm focused on financing innovation in healthcare and biotechnology across development stages, from early discovery to later-stage growth. It backs therapeutics, diagnostics, health technology, and digital health ventures in Europe, leveraging ties with research centers and hospitals to translate scientific advances into clinical and commercial success. The firm operates with a Europe-wide reach, with a notable presence in France, and emphasizes collaborating with researchers and entrepreneurs to support impactful, sustainable healthcare solutions.

Nextech Invest is a Zurich-based venture capital and private equity firm established in 1998 that focuses on healthcare and life sciences, with a strong emphasis on oncology and precision medicine. It backs early through late-stage companies worldwide, including therapeutics, drug discovery, biotechnology, diagnostics, and medical technologies, and pursues co-investment opportunities. The firm supports portfolio companies through their lifecycle from scientific validation to value creation and often takes board seats. Exits are targeted within a few years, frequently via trade sale. With a global footprint across Europe, North America and other regions, Nextech Invest seeks to accelerate cancer medicines and other life science innovations.

Seventure Partners is a Paris-based venture capital firm founded in 1997 that supports European startups in digital technologies and life sciences. With around €1 billion under management, it backs companies from early to growth stages, offering capital and strategic guidance. Its focus spans Life Sciences (Biotech, Healthcare, Nutrition) and Tech/Digital (B2B SaaS, Fintech, Retailtech, Cybersecurity), with additional interests in Sports & Wellbeing and the Blue Economy. The firm leverages a strong network and in-house expertise to help portfolio companies accelerate development, scale, and access new markets. It operates across Europe and collaborates with entrepreneurs to foster innovation and long-term growth.

Lux Capital is a New York-based venture capital firm founded in 2000 that funds seed- and early-stage companies, with occasional growth investments, in science- and engineering-driven sectors. It backs ventures applying scientific research to commercial applications across artificial intelligence, biotechnology, advanced materials, electronics, aerospace and space technology, satellites, drones, robotics, synthetic biology, genomics, 3D printing, and related infrastructure. The firm provides capital alongside strategic input on product development, team building and long-term positioning, taking an active role to help translate complex innovations into scalable businesses. With offices in New York and Silicon Valley, Lux has helped launch more than 20 companies and manages several billion dollars in assets. It emphasizes deep scientific insight, cross-disciplinary collaboration, and an early-stage focus, aiming to connect portfolio companies with markets and industry leadership.

High-Tech Gründerfonds is a Germany-based venture capital firm that provides seed and early-stage financing to technology-focused startups. Founded in 2005, it operates as a public-private partnership with government and corporate investors to support German and European tech companies across digital technology, industrial tech, life sciences, chemistry and related areas. The firm offers capital and expertise to help startups move from concept to market, typically engaging in initial rounds and follow-on funding to accelerate growth. Since inception it has backed hundreds of startups and supported follow-on rounds, helping to stimulate innovation and entrepreneurship in Germany.

Third Rock Ventures is a Boston-based venture capital firm focused on life sciences and healthcare. The firm invests in start-up and early-stage companies across biotechnology, pharmaceuticals, medical devices, diagnostics, therapeutics, and related information technologies, seeking to build companies with the potential to transform patient care. It typically leads initial investments and pursues strategic collaborations to accelerate development, while taking an active role in portfolio companies through management and governance involvement. The firm emphasizes bold science and disruptive approaches, including oncology, cardiovascular devices, and AI-enabled or data-driven healthcare solutions. Founded in 2007, Third Rock maintains a U.S.-centred portfolio with offices in San Francisco, and collaborates with larger pharmaceutical and biotechnology partners to advance products from discovery to market.

European Investment Fund is the European Union’s financing arm for small and medium-sized enterprises and mid-caps, providing financial instruments to improve access to affordable financing throughout a business lifecycle. It leverages its capital base to attract private investment through guarantees and equity funding, fostering public-private partnerships and crowding in lenders and investors to support SMEs and startups across EU member states, candidate countries, and EFTA. The EIF focuses on innovation, growth, competitiveness, social impact, and sustainability, and supports financing for sectors such as information technology, life sciences, energy, and manufacturing, helping close funding gaps and contribute to Europe’s economic resilience and strategic autonomy.